Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03482050 | A Study to Evaluate Transplantation of Astrocytes Derived From Human Embryonic Stem Cells, in Patients With Amyotrophic Lateral Sclerosis (ALS) | PHASE1 | COMPLETED | 16 | — | — | Apr 12, 2018 | Jun 22, 2020 | Jan 15, 2021 | 1 | Israel |
Safety and tolerability assessment will be based on treatment emerged adverse events
| Arm | Type | Description |
|---|---|---|
| AstroRx | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| AstroRx | BIOLOGICAL | Astrocytes derived from human embryonic stem cells |
Main Inclusion Criteria: 1. El Escorial criteria for probable or definite ALS 2. Males and and non pregnant females between 18 and 70 years of age 3. Patients with an ALS-FRS-R score of at least 30 with an ALS diagnosis of two years or less 4. No history of active psychiatric disorder. Patients rec...